ATE440094T1 - Fumagillolderivate und verfahren zu deren herstellung - Google Patents

Fumagillolderivate und verfahren zu deren herstellung

Info

Publication number
ATE440094T1
ATE440094T1 AT02738910T AT02738910T ATE440094T1 AT E440094 T1 ATE440094 T1 AT E440094T1 AT 02738910 T AT02738910 T AT 02738910T AT 02738910 T AT02738910 T AT 02738910T AT E440094 T1 ATE440094 T1 AT E440094T1
Authority
AT
Austria
Prior art keywords
angiogenesis
production
fumagillol derivatives
fumagillol
psoriasis
Prior art date
Application number
AT02738910T
Other languages
English (en)
Inventor
Cheol-Kyu Han
Jeong-Hyeok Yoon
Seung-Moak Kim
Nam-Doo Kim
Byung-Ha Chang
Jee-Young Lee
Tae-Bo Sim
Original Assignee
Equispharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0060017A external-priority patent/KR100455900B1/ko
Priority claimed from KR10-2002-0029915A external-priority patent/KR100483836B1/ko
Application filed by Equispharm Co Ltd filed Critical Equispharm Co Ltd
Application granted granted Critical
Publication of ATE440094T1 publication Critical patent/ATE440094T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
AT02738910T 2001-09-27 2002-06-11 Fumagillolderivate und verfahren zu deren herstellung ATE440094T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2001-0060017A KR100455900B1 (ko) 2001-09-27 2001-09-27 새로운 푸마질롤 유도체 및 그의 제조방법
KR10-2002-0029915A KR100483836B1 (ko) 2002-05-29 2002-05-29 푸마질롤 유도체 및 그의 제조방법
PCT/KR2002/001102 WO2003027104A1 (en) 2001-09-27 2002-06-11 Fumagillol derivatives and preparing method thereof

Publications (1)

Publication Number Publication Date
ATE440094T1 true ATE440094T1 (de) 2009-09-15

Family

ID=26639368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738910T ATE440094T1 (de) 2001-09-27 2002-06-11 Fumagillolderivate und verfahren zu deren herstellung

Country Status (5)

Country Link
US (3) US7087768B2 (de)
EP (1) EP1436286B1 (de)
AT (1) ATE440094T1 (de)
DE (1) DE60233420D1 (de)
WO (1) WO2003027104A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE440094T1 (de) * 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1841761A4 (de) * 2005-01-26 2008-10-29 Chong Kun Dang Pharm Corp Fumagillolderivate oder verfahren zur herstellung von fumagillolderivaten, und pharmazeutische zusammensetzungen, die diese enthalten
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) * 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
EP2646016B1 (de) 2010-11-29 2017-05-17 Zafgen, Inc. Behandlung von fettleibigkeit mittels nicht-täglicher verabreichung von - 6 - 0 - (4 - dimethylaminoethoxy)-cinnamoylfumagillol
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
FR2973376B1 (fr) * 2011-03-28 2013-05-10 Atlanthera Derives utiles dans le traitement ou la prevention de tumeurs osseuses
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
EP2850079B1 (de) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol derivate,verfahren zu deren herstellung und deren verwendung
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
AU2014250983B2 (en) 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
EP3402529A1 (de) 2016-01-11 2018-11-21 Syndevrx, Inc. Behandlung von durch stoffwechselstörungen hervorgerufen tumoren
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
EP0357061B1 (de) * 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenese hemmendes Mittel
ATE150750T1 (de) * 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) * 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
DE69001187T2 (de) 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (de) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP0799616A1 (de) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Orale Zubereitung enthaltend ein Fumagillolderivat
DE19653036A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptidderivate
US6207704B1 (en) * 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
ATE440094T1 (de) * 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
WO2003037330A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors

Also Published As

Publication number Publication date
EP1436286A1 (de) 2004-07-14
US20040242681A1 (en) 2004-12-02
DE60233420D1 (de) 2009-10-01
US7087768B2 (en) 2006-08-08
US20070149613A1 (en) 2007-06-28
EP1436286A4 (de) 2004-12-15
US20060276512A1 (en) 2006-12-07
EP1436286B1 (de) 2009-08-19
WO2003027104A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
ATE440094T1 (de) Fumagillolderivate und verfahren zu deren herstellung
NL300933I2 (nl) Letermovir
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
GT200100183A (es) Derivados de quinolina y quinazolina.
EA200400368A1 (ru) Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
DK1613304T3 (da) DPP-IV-inhibitorer
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
SE0301888D0 (sv) New use VII
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
WO2005009975A3 (en) Benzimidazole derivatives as mek inhibitors
IS8230A (is) Setið 2-amínótetralín til notkunar við meðferð á þunglyndi
BRPI0518752A2 (pt) 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
ATE291024T1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
BR0312863A (pt) Derivados de aldeìdo de polietileno glicol
BR0008682A (pt) 3-amino-3-arilpropan-1-ol, processo para sua produção, seu uso e medicamento
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
UY26133A1 (es) Derivado sustituido de pirazol.
CY1112191T1 (el) Παραγωγο πυραζολοπυριμιδινης
ECSP055844A (es) Nuevos compuestos triciclicos
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties